Welcome to our dedicated page for Grifols S A news (Ticker: GRFS), a resource for investors and traders seeking the latest updates and insights on Grifols S A stock.
Grifols, S.A. reports developments tied to its global healthcare business, including plasma-derived medicines, diagnostic technologies, transfusion-medicine solutions and biological supplies for research, clinical trials and pharmaceutical or diagnostic manufacturing. Its business references include Biopharma, Diagnostic, Bio Supplies and other activities such as manufacturing services, research and complementary pharmaceutical products.
Recurring news themes include product and regulatory updates for plasma-protein therapies, such as fibrin sealant for surgical bleeding, and research programs that use plasma assets, AI, proteomics and real-world data. Coverage also includes Chronos-PD work led by Alkahest, shareholder communications on board composition and disclosure, and capital-market topics affecting Grifols' listed shares in Spain and the United States.
Grifols announced the launch of the world's first scientific journal dedicated to plasma science, coinciding with the 70th anniversary of the plasmapheresis technique. Titled Plasmatology, the journal aims to be the leading reference in plasma research, publishing peer-reviewed articles covering various topics in plasma science. Grifols will provide an educational grant over the next two years to support the journal's establishment. This initiative reinforces Grifols' commitment to research and scientific advancement in plasma-derived therapies, enhancing its leadership position in the industry.
Grifols (NASDAQ: GRFS) has been recognized as the top vendor in IV Workflow Management for its PharmacyKeeper Verification software in the 2021 Best in KLAS report, marking its fifth consecutive year of receiving this accolade. This ranking reflects exceptional scores in quality, value, and user ease among a range of hospitals and systems. The company emphasizes its commitment to enhancing pharmacy operations, including a recent initiative to support COVID-19 vaccine preparation. Grifols is dedicated to safety and efficiency in healthcare settings through innovative solutions.
Grifols, a global leader in plasma-derived medicines, announced its PharmacyKeeper Verification software ranked No. 1 in IV Workflow Management in the 2021 Best in KLAS report, marking its fifth consecutive year at the top. This accolade reflects exceptional scores in quality, value, and ease of use across various healthcare facilities. Grifols has committed to supporting clients with COVID-19 vaccine workflows, showcasing its dedication to industry needs. The Best in KLAS rating, based on provider feedback, signifies Grifols' excellence in healthcare technology and services.
Grifols has announced a clinical trial set to commence in February 2021 in Spain to evaluate the safety and efficacy of a new COVID-19 treatment utilizing Gamunex®-C, which contains anti-SARS-CoV-2 polyclonal antibodies from recovered plasma donors. The trial will involve approximately 800 asymptomatic patients testing positive for the virus. This treatment is designed to offer immediate post-exposure protection, particularly for vulnerable populations. Results are anticipated in Spring 2021, with the potential to enhance existing vaccination efforts.
Summary not available.
Grifols (NASDAQ: GRFS) announced a partnership with TRC Healthcare on November 12, 2020, to enhance pharmacy education. This collaboration integrates Grifols' PharmacyKeeper, a leading IV Workflow Management system, with TRC's educational resources. The aim is to improve patient safety and care by providing pharmacists with up-to-date drug information and training. The partnership underscores Grifols' commitment to advancing IV room operations and reinforces its leadership position in the pharmacy technology market.
Grifols has commenced a randomized controlled clinical trial for its anti-SARS-CoV-2 hyperimmune globulin aimed at treating COVID-19. Funded by NIAID, this Phase 3 trial will assess safety, efficacy, and tolerability in 500 hospitalized adults across 58 hospitals in 18 countries. This treatment leverages convalescent plasma from recovered COVID-19 patients, potentially enhancing immune response to reduce severe illness risk. Grifols has quickly established a convalescent plasma collection program and is actively participating in over 25 COVID-19 initiatives.
Grifols has launched a clinical trial for its anti-SARS-CoV-2 hyperimmune globulin, aimed at treating COVID-19. This randomized controlled trial will assess the product's safety and efficacy in 500 hospitalized adults across 58 hospitals in 18 countries, including the U.S. and Spain. Funded by NIAID, the trial seeks to enhance immune responses when symptoms appear. Grifols leads multiple COVID-19 initiatives and has developed a robust plasma collection program to support treatment efforts during the pandemic.
Grifols has acquired a plasma fractionation plant in Montreal and 11 plasma collection centers in the U.S. from GC Pharma for a total of US$460 million. This move establishes Grifols as the only large-scale commercial manufacturer of plasma products in Canada, with an annual capacity of 1.5 million liters. The investment aims to enhance self-sufficiency in plasma-derived medicines in Canada and expand Grifols' plasma collection network. The transaction will significantly bolster Grifols' presence in North America, targeting a market known for high plasma consumption.
Grifols has acquired a plasma fractionation plant and purification facilities in Montreal, Canada, for US$370 million, along with 11 U.S.-based plasma centers for US$90 million. This investment, which does not require external financing, marks Grifols as the only large-scale plasma products manufacturer in Canada, enhancing its capacity to produce essential medicines. The acquisition supports Canada's self-sufficiency in plasma-derived therapies and aligns with Grifols' strategy for international growth, particularly in North America, where plasma consumption rates are high.